Jennifer Doudna, Fyodor Urnov want to streamline gene editing studies with Danaher's help
Jennifer Doudna wants to create a new blueprint for developing gene editing therapies for rare diseases — an area where there’s been limited diversity in the conditions being addressed because many aren’t seen as profitable.
The Innovative Genomics Institute, a nonprofit founded by Doudna, is partnering with life science tools company Danaher for four years to develop gene editing therapies for two rare genetic diseases, and the collaborators plan to share their playbook widely in hopes of spurring more development of gene editing treatments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.